+41 61 316 81 11
We combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries. We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. Our solutions improve life quality by preventing illness, enabling healthier lifestyles and supporting a safe environment. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.
Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.
Founded in 1897 in the Swiss Alps, Lonza today operates across more than 100 sites and offices and employs approximately 15,500 full-time employees worldwide. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion.
With more than a century of experience, we have a unique capability to connect biotech expertise with fine chemical know-how, which allows us to provide the best solutions for our customers’ success.
By continuously developing our technologies, we enable our customers to meet some of the world’s greatest challenges such as the vital need for disease prevention and treatment, abundant food, advanced materials, and enhanced hygiene and wellness.
Around the world we are driven by our firm commitment to high quality and operational excellence across the regions, functions and markets we serve, every day.
Empowerment, trust and integrity govern how we do business and how we interact with each other. As individuals and as teams, we are making this the place to go, stay and grow.
As one of the world’s most renowned companies for contract development and manufacturing, Lonza Pharma & Biotech is recognized for our reliable, high-quality services, our global capacity, our innovative technology platforms, and our extensive experience. From 2013 to 2016, our contributions supported 36% of launches with small-molecule breakthrough designation. In 2016 alone, we provided manufacturing services for more than 50 commercial molecules and conducted more than 250 development programs. We have helped launch pioneering autologous cell therapies.
Success for us is when you, as our partner, are fully satisfied. We continuously improve and innovate to meet your expectations and improve your chances of business success. Our broad capabilities span across biologics, small molecules, bioconjugates, and cell and gene therapies. We manage projects from pre-clinical stage through to commercialization, and our expertise covers both drug substance and drug product.
We believe that the best outcome – for you and for your patients – can only come as a result of a successful collaboration. Together, we can solve the next challenge and bring your next medicine to life.
Can you reduce attrition rates and cost during the development of biotherapeutics? Discover more in our webninar De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression & Genetic Characterisation Tools #Biotechnology #Webinar https://t.co/rDNwRFzGz4 pic.twitter.com/A4tcowmyy6— Lonza (@LonzaGroup) June 30, 2020
We are excited to announce the second episode of #AViewOn #podcast about using cell-penetrating peptides for #cancer treatment. Listen to Lonza's @DrHestericova speaking with Per Hellsund and Vishwas Paralkar of @Cybrexa— Lonza (@LonzaGroup) June 29, 2020
Access the podcast episode here: https://t.co/wDeVSAzQv3 pic.twitter.com/YDOyWuG8tf